DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% Drug Patent Profile

When do Dopamine Hydrochloride And Dextrose 5% patents expire, and when can generic versions of Dopamine Hydrochloride And Dextrose 5% launch?

Dopamine Hydrochloride And Dextrose 5% is a drug marketed by B Braun and is included in one NDA.

The generic ingredient in DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% is dopamine hydrochloride. There are nine drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the dopamine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Dopamine Hydrochloride And Dextrose 5%

A generic version of DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% was approved as dopamine hydrochloride by HOSPIRA on February 4^th, 1982.

Summary for DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	96
Clinical Trials:	1,103
DailyMed Link:	DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% at DailyMed

Recent Clinical Trials for DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Krzysztof Bankiewicz	PHASE1
Cairo University	NA
Tanta University	NA

See all DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% clinical trials

US Patents and Regulatory Information for DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
B Braun	DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%	dopamine hydrochloride	INJECTABLE;INJECTION	019099-002	Oct 15, 1986		DISCN	Yes	No
B Braun	DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER	dopamine hydrochloride	INJECTABLE;INJECTION	019099-003	Oct 15, 1986		DISCN	Yes	No
B Braun	DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%	dopamine hydrochloride	INJECTABLE;INJECTION	019099-004	Oct 15, 1986		DISCN	Yes	No
B Braun	DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER	dopamine hydrochloride	INJECTABLE;INJECTION	019099-001	Oct 15, 1986		DISCN	Yes	No

Market Dynamics and Financial Trajectory for Dopamine Hydrochloride and Dextrose 5%

Last updated: February 10, 2026

Overview:
Dopamine Hydrochloride combined with Dextrose 5% is primarily used as an inpatient vasopressor and inotropic agent for managing shock and heart failure. Its market is driven by hospital demand for critical care pharmaceuticals, influenced by healthcare infrastructure, regulatory policies, and clinical guidelines.

Market Size and Growth:
The global market for inotropic and vasopressor drugs, including dopamine formulations, was valued at approximately $490 million in 2021. It is projected to grow at a compound annual growth rate (CAGR) of about 4.5% through 2028, reaching roughly $660 million.

Regional insights include:

• North America: Dominates with an estimated 50% of the market, supported by advanced healthcare infrastructure and high critical care demand.
• Europe: Accounts for approximately 25%, with growth driven by aging populations and expanding critical care services.
• Asia-Pacific: Offers the fastest CAGR of around 6%, fueled by increasing hospital admissions, healthcare investments, and expanding ICU capacities.

Drivers of Market Growth:

• Rising prevalence of cardiovascular diseases requiring acute management.
• Increased hospital admissions due to trauma, sepsis, and cardiac events.
• Growing adoption of critical care protocols emphasizing vasopressor use.
• Technological advances leading to improved drug formulations and delivery methods.

Key Market Players:

• Pfizer (as of 2022, its product "Dopamine Hydrochloride" is approved in multiple countries).
• Hikma Pharmaceuticals.
• Dr. Reddy’s Laboratories.
• Fresenius Kabi.
• Sun Pharma.

These companies focus on manufacturing, expanding regional distribution, and gaining regulatory approvals.

Regulatory and Pricing Trends:

• US FDA approvals require demonstrating safety, efficacy, and manufacturing consistency.
• Pricing remains variable; in the US, negotiated reimbursement rates influence hospital purchasing decisions.
• Global price pressures from generic drug proliferation impact revenue potential, especially post-patent expiration.

Patent Landscape:

• Specific patents for dopamine formulations generally have expired globally, increasing generic competition.
• Companies invest in reformulations or combination therapies to extend market exclusivity.

Financial Trajectory:

• Post-patent expiration, revenue tends to decline due to generic competition.
• Smaller firms may gain market share by offering lower-cost alternatives.
• Investment in manufacturing capacity and regional expansion supports revenue stability for leading firms.

Emerging Trends:

• Development of more stable, ready-to-use formulations to improve bedside use.
• Adoption of combination therapies to multiplex inotropic and vasopressor effects.
• Digital health integrations for infusion monitoring, reducing wastage and improving outcomes.

Challenges:

• Price competition from generics.
• Regulatory hurdles for new formulations.
• Variability in hospital formulary preferences.

Conclusion:
The dopamine hydrochloride and dextrose 5% market remains stable but mature, with growth driven by critical care needs. Revenue peaks are often associated with patent exclusivity and innovations in delivery, but generic competition exerts downward pressure. Strategic regional expansion and product differentiation position companies to optimize financial outcomes.

---

Key Takeaways:

• The global market for dopamine hydrochloride with dextrose 5% is projected to grow modestly, reaching around $660 million by 2028.
• North America holds majority market share, while Asia-Pacific exhibits the highest growth rate.
• Patent expirations have increased generic competition, pressuring prices and revenues.
• Innovations in formulations and delivery methods influence market sustainability.
• Regulatory and reimbursement policies significantly affect market access and profitability.

---

FAQs

1. How does patent expiration influence revenue for dopamine hydrochloride products?
   Patent expiration allows generic manufacturers to enter the market, which typically reduces drug prices and lowers revenue for original patent holders.

2. What are emerging product development trends for dopamine formulations?
   There is a focus on creating more stable, ready-to-use formulations, and combining dopamine with other agents to improve bedside efficiency and patient outcomes.

3. How do regional healthcare policies impact market growth?
   Increased healthcare spending, expanded critical care infrastructure, and supportive regulatory policies drive growth in regions like Asia-Pacific.

4. What role does hospital formulary acceptance play?
   It determines the adoption rate within healthcare facilities; drugs favorably listed or preferred tend to maintain higher market share.

5. Are there new regulatory challenges for dopamine hydrochloride products?
   Yes, especially with new formulations, delivery systems, or combination therapies, which require comprehensive clinical data and approval processes.

---

Sources:
[1] MarketsandMarkets, "Vasopressor and Inotropic Agents Market," 2022.
[2] Fortune Business Insights, "Global Critical Care Drugs Market," 2022.
[3] US FDA, Drug Approvals and Labeling, 2021.